Snapshot from Sep 11, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

Fecal Transplant Increases Peanut Tolerance

Analysis based on 10 articles · First reported Aug 05, 2026 · Last updated Aug 25, 2026

Sentiment
40
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The findings could spur investment in microbiome-based therapies for food allergies, potentially benefiting biotech companies developing such treatments. However, the small trial size and preliminary nature mean significant market impact is unlikely in the near term.

Biotechnology Pharmaceuticals Healthcare

A phase 1 clinical trial at Boston Children s Hospital, published in Science Translational Medicine, tested whether fecal microbiome transplantation (FMT) could increase peanut tolerance in adults with severe peanut allergies. Fifteen participants received oral encapsulated FMT from healthy donors; six showed increased tolerance, with some tolerating up to 600 mg of peanut protein. The study identified a mechanism involving bile acid metabolites and RORγt+ regulatory T cells, and mouse experiments confirmed the protective effect. Researchers plan a phase 2 trial with a purified formulation. Experts caution that larger studies are needed before clinical use.

80 Rima Rachid led study
80 Talal Chatila led study
30 United States — Food and Drug Administration approved FMT for C. diff Clostridioides difficile
20 Mohammad Bakhtiar commented on study
per
Senior researcher who co-led the study, enhancing his reputation in immunology.
Importance 90.0 Sentiment 60.0
per
Lead author and director of allergy programs, advancing her research on microbiome therapies.
Importance 90.0 Sentiment 60.0
govactor
Regulatory body; FMT is already approved for C. diff, but not for allergies.
Importance 30.0 Sentiment 30.0
per
Provided expert commentary, adding context but not directly involved.
Importance 20.0 Sentiment 0.0
priv
Affiliated with commentator, minimal direct impact.
Importance 10.0 Sentiment 0.0
priv
Reported on the study, increasing public awareness.
Importance 10.0 Sentiment 0.0
oth
Reported on the study, increasing industry awareness.
Importance 10.0 Sentiment 0.0
oth
Existing approved indication for FMT, providing safety precedent.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.